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Thirtyeight patients who had induoibk sustained rentiicular 
tsrhyeardia during baseline programmed &trieal stimulation 
underwent ckctrcphysiologb tenting atler bath intravenous and 
oral adloinklration of pmcainsmide. Each bad prean,d ctini- 
catty with docrmen,ed sustained ventricular tachycardia or out OT 
hospitsl cardttc awes, nut a%socinted with acde rnywardiat 
infarctian. 
lmean 9.0 * 3.3 p&n,) nod oral (8.8 + 3.1 Am,) plasma 
procainamide kvek. 
In the additiwal I5 patier& Grwp II) rustairwd wntricdar 
Bch)arrh)lbmia rematned inducibk on intraemw procaine- 
mbtr therapy and the ptknts were re,a,rd on oral therap, *i,b 
similar plasma mncentratian tp = 0.0% In sewn patients (47%) 
sustained rentrkulv bxhvarrhvthmia was nonindtihk on treat- 
ment with oral pi’ocainar&e t&an plasma lcwl7.6 -c 2.7 pghnl) 
a&r failure ol intrawncms prwabmmtde ,mevl plasma level 
10.3 + 2.3 @g/In,,. 
In 23 patie,%tr (61%) Graup I) the arrhythmia lwcame nonin. 
ducihle durinp, an intrawwus infusion of procainamide. Oral 
proc~nemtdc~was subsequently sdmbda,ereb and relesting was 
em’rted out after dose titra,ian to match ptarma concentration at
tbe end d the inhilveienwr study. Among the 23 patienlr in Group 
I the mean W SD) ptasmaprwinamide level rapl.2 22.8 p&d 
after intravenous dosing and 7.9 2 2.5 &ml after oral dosing 
(p = 0.09). In IS (65%) of the 23 p~tie,,b, sWained ventricular 
arrhythmia was inducibk on orat therapy with comparable 
plasma procaiwmide trvds ,intrwen.ws = 6.3 f 2.1 &d. wat 
= 7.: f 2.1 ,&,I). The olber eigh, pattats (35%) bad concur- 
dant responsrs lo repeat tes,iag with comparable intrwenous 
Programmed electrical s,imula,ion has become an accepted 
means for identifying effeclive antiarrhylhmic therapy for 
patients with documented sustained ventricular tachyer- 
rhythmias (l-4). Drug tesling with intravenous procaine- 
mide is commonly used during ekctrophywlogic studin to 
assess antiarrhythmic efficacy of this agent immcdiawly and 
on a long-term basis t5-9). In prior s,udiei t IO) the results of 
intravenous and oral procainamide therapy with ,he ULC of 
programmed eleclricll stimulation as en end point and 
matched plasma drug levels of intravenous and oral rherapy 
appeared concordant. suggesting that \hor,-,erm Wang wth 
intravenous procainamidc i3 prediclive of long-term cbmcal 
response 10 this age”,. 
In ~onc,usicm. in pa,kn& with indpdbk ver&rtcukr arrbytb- 
mia a, has&w eltimohvstatie study the remmw to bume- 
nws pmcainamtde d& II* p&t thc‘&tmph&logic elkc, cd 
rubwquentoraladlnlnisrmtionolpmcainarni~ in daesthat)ield 
Gnilar or slightly higher plasma mnrentratians. Thus. ,lRre 
appars LO br E,tk adxanlsge lo ekc,mpbysiok@ drug tnting 
rbb inlrawnous praaiamdde. 
The purpose of this study was to determine whether both 
powive and negdive drug tes,ing resuI,s wiih imravenous 
procamamlde at the lime of eleclrophysiologic wdy can 
prcdicr the ekcfrophysiotogic response moral procainarmde 
in pa,icn,\ nith sustained ven,ricular ,achyarrW!mias. 
Study patients (Table II. Thiny_eigh, patients were en- 
rolled in this study (28 men and 10 women. ranging in age 
from 33 10 81 years [mean -r SD 64 ? 10.31). Tbiny-one 
p&n,\ had significant coronary anery disease defined as 
>75R s,en&s of one or more major coronary arteries and a 
prior hlstorv of mvocardial infarction. two patients had 
hyperwophic cardidmyopathy. ,wo had idiopathic dilated 
cardiomyopathy and two had no documented structural 
hear, diwse. The mean ejection fraclian was 33 f Ih.S% 
,ralge 14% 10 755). 
T/w c hh nl rkornrrrri~lk-r of rlk pnrirnrs OTC w!wn(1- 
rixd in Tub/e 1. Thirty-one patienls had one or more 
documented episodes of sustained ventricular tachycardia 
and wen patients had a history of cardiac arrest with 
documented ventricular fibrillation. All patients had induc- 
ible sustained ventricular tachyarrhythmias. which were 
reproducibly imtiated during programmed stimulation. 
Twenty-live patienta had sustained monomorphic ventricu- 
lar tachycardia. six had ventricular Rulter and seven had 
ventricular fibrillation induced during baseline programmed 
stimulation study. Ventricular tachyarrhythmiar induced in 
the baseline slate and after inwavenously administered pro- 
cainamide were similar in configuration. 
Ekclrophysiologic teslinp pmtocal. Studies were per- 
formed with patients in a nonsedakd postabsorptive state 
after they had given informed consent. Baseline electrophys- 
iologic study was performed after all antiarrhythmic agents 
had been discontinued for at least 5 half-lives: no patisnt had 
been receiving amiodarone. Two to four quadripolar elec- 
trode catheters were introduced percutaneously or by cub 
down and positioned under Ruororcopic guidance in the high 
right atrium. His bundle position, right ventricular apex and 
right ventricular outflow tract. intracardiac recordings were 
filtcrcd at 30 to 504 Hz and displayed simultaneously with 
three surface electrocardiographic (ECG) leads (I.11 and V,) 
on a 16channel physiologic recorder(VR-16, Electronics for 
Medicinel. On-line recordings were obtained with an elec- 
tromagnetic recorder (Gould IOC0.S). lntrncardiac slimula- 
ticn was performed with a programmable stimulator IBloom) 
set to deliver rectangular pulses of I ms duration ‘i: twice 
diastolic threshold. Prosrammed ventricular stimula ‘an in- 
cludcd up to three ven&ular extrastimuli from up to two 
riaht ventricular sites lriaht ventricular awx and right ven- 
tr;cular outflow tract) at up to two p&d cycle-lengths 
between 600 and 400 ms. Rapid ventricular burst pacing was 
also performed using g to IO impulses at 50 ms cycle length 
decrements begmning at 600 ms and continuing to 2:I 
capture. 
Pmcainamide administration. After documentation of a 
reproduciblv inducible ventricular tachyarrhythmia, pro- 
c&amide ias administered intravenously by a double infu- 
sion technique. An initial infusion at a rate of SO mglmin 
delivered a dose of IO to IS m&g body weigh; to8 total dose 
of IW to I.800 ma. Blood oressure was monitored with a 
rphygmomanomer~r every ‘5 min during the initial drug 
infusion. After the bolus infusion was completed, a wntin- 
uous infusion of procainamide at a rate of 2 to 5 mgmin was 
initiated to maintain a stable plasma concentration. After 
procainamide administration, the complete stimulation pro- 
tocol was renated. Stimulation was continued until ventric- 
ular tachycka or fibrillation was induced or ventricular 
refractoriness was reached. At the end of the study, a blwd 
aample wasobtained for measuring the plasmacon&ration 
of procainamide. Procainamide levels were measured with a 
fluorescence polarization immunoassay (II). 
After completion of the initial study, oral sustained re- 
leaed procainamide was given for 3 to 6 days in a dose 
ranging from SW to 1.75U mg every 6 h. Oral dosing was 
titroted to achieve a plasma concentranon silp!!ar to that 
oblained intravenously at the time of the initial study or that 
maximally tolerated by the patient. All patients underwent a 
repeat ofthe stimulation protocol used in the baseline study. 
Plasma pmcainamide levels were measured from samples 
obtained at completion of the study protocol. 
Definitions. Sustained ventricular tachycardia was de- 
tined a> a whyarrhythmia lasting >30 s or requiring termi- 
nation by ventricular stimulation or direct-current cardiover- 
sion before 30 s because of symptomatic hypotension. 
Nonsustained ventricular tachycardia was defined as 26 
consecutive beats and terminating spontaneously withm 
30 s. Reproducible inducibilil‘, refers to a ventricular ar- 
rhythmia induced at least twice by the same protocol during 
programmed or incremental ventricular stimulation. 
Statislkss. Results are reported as the mean vaiues t SD. 
Statirtical analysis was performed with use of Student’s 
I test for paired and nonpaired data. A p value < 0.05 was 
considered statistically significant. 
Results 
noninducible after in&&e&us procainamide. sustained veo- 
Made al induction (Table 2). The 38 patients were cld,~~- 
lied into two groups on the basis of their response to the 
initial intravenous studv tn,~ls of orocainamide. The 23 
tricular artltvthmia was inducible in I5 (65%) during treat- 
patients whose arrhyth& became &inducible after mtra- 
venous procainamide constitute Group I and the 15 whose 
arrhythmia remained inducible are included as Group II. 
Among the 23 Grow I patients whose arrhythmia was 
mtravenou~ and oral therapy. The respective wlues in 
responders were 8.1 + 3.5 and 8.7 2 3.6 &I,. 
In :he t5 paucnts in Group II who had unsuccessful 
intravenou procamamide therepy the plasma kwl of pro- 
cainamide was 9.4 i 2.0 &ml after the intravenous drug 
infusion. When these pattents were relested on oral procain- 
amide therapy. the mean plasma drug level was 8.0 z 
2 I pgml (p = 0.06). The mean plasma concentntion anwn; 
the ,even re>pond% to oral therapy after unsuccessful 
intravenous therapy was 7.6 2 2.7 after oral administration 
ver-w 10.3 + 2.3 &ml after intravenous administration: the 
eight pat~en!s who did not respond to oral or intravenous 
procainamidr therapy had plasma concentrations of 8 3 1; 
I.5 and 8.7 z I.5 &ml. respectively. during oral and 
intravenous doang. 
1. are shoun in Figure I. Of the 23 patient;. IS (65%) had; 
discordant rexwonse to oral orocainamide with equal or 
Prrirrd ploma p,m,ner,,id~ m,,,cw,m~io,~ dam for con- 
wrdu,zcu and discordonce OJ-dmp ruspcmsr. as assessed by 
programmed ventricular stimulation in the oatients in Grow 
tnent with &al procainamide. On comparing the &se of 
arrhythmia inducibility between baseline and oral procaina- 
mide testing. we observed that in 8 of rhe 15 patients the 
arrhythmia was induced by the same pacing protocol re- 
quired at baseline study, in 3 ir was induced by a less 
aggressive protocol and in 4 arrhythmia induction required a 
more aggressive protocol after oral procainamide therapy 
than was required during baseline study. When comparing 
the S responders on oral procainamide therapy with the I5 
nonresponders. we found no difference in eaxe of arrhythmia 
inducibility between these two groups at baseline study. 
The I5 parienfs in Grmp II had nnsarcussfld bm”\r~t”ur 
procainomide rhrrapy and subsequently received oral pro- 
cainamide titrated to matching plasma levels. lo 7 (47%) of 
the I5 patients. the arrhythmia became noninducible on oral 
therapy: in 5 of the 7 it was induced by the same protocol 
both at baseline study and after intravenous procainamide 
(that is, there was no change in ease of inducibilhy after 
intravenous administrationl. When the seven responders and 
eight nonresponders on oral therapy were coo&red. there 
was no difference between the two groups in ease of arrhyth- 
mia inducibility at baseline study. 
Pmeainamide plasma levels (Table 21. Among the 23 
patients in Group 1. mean procainamide concentration was 
7.2 + 2.8 &ml after intravenous administration and 7 9 ? 
2.5 &ml after oral therapy tp = 0.09). In the I5 Gmup 1 
patients who responded to intravenous but not to oral 
procainamide therapy. the procainamide level was 6.3 c 
2.1 &III after intravenous and 7.5 t !.I pglrnl after oral 
therapy. The remaining eight patients. who had a concordant 
response to intravenous and oral therapy. had a plasma 
procainamide concentration of 9.0 z 3.3 &ml rdkr inm- 
veooos and 8.8 + 3. I pglml during oral therapy. Comparison 
of nonresponder, with responder, to oral procainamide 
therapy revealed that nonresponders kdd plasma drug kvcls 
of 6.3 + 2.1 and 6.8 f 1.8 &ml. respectively. after 
slightly higher~plasma drug cdncentrations: 8 (35% had a 
concordant response to oral therapy. Of the 23 patients in 
this group. 2 had intrwnous plasma procainamidc levels of 
r4 rn@nI due to a hypotensive intolerance response 10 an 
intravenous bolus infusion at the time of drug testmg. 
P<,;wtl plnwu procrrirwzdd~ kwls for ,he I5 p&ed, 
who II’CW rrs1cd on urcd rhemp~ “f&v wsamss/nl ilmm- 
WK~ rhrmp~ are shown in Figure 2. Eight of the I5 pauents 
had a concordant response with oral therapy ar marching 
levels; Ihe olher 7 had a discordant response except for I 
patient who did not tokrare oral pmcanamide therapy at 
higher dosing and had a good therapeutic response after oral 
drug tesung at a plasma level of 3 mdml. 
E&t on tachyeanik cycle length. Fifteen patients in 
Group I had ventricular tachycrudia induced on oral procain- 
amide therapy at it plasma level similar to that oithc baseline 
wdy. Among these 15 padems. the cycle length of Ihc 
ventricular rachycardia increased by St f 36 ms after oral 
procamamide therapy. Among the Group II patients with 
&mcordunt responses. there was a greater prolongalion of 
the tachycardia cycle length with intravenous than during 
oral proainamide II27 i 66.6 vs. 66.7 + 41.6 ms when 
compared with the baseline state). In this group the mean 
ddference m tachycardxa cycle length between baseline and 
intravenous procainarmde therapy was 71.4 ? 37.6 rns. 
Discussion 
Previous studks. Prior reports I IO.I?I have suggested 
that the rewlts of awe drug testing with intravenous 
procamamide predicts ourcome with cm’ therapy wilh a 75% 
to 10% concordance when comparable worn cortceot~a- 
tionc are achieved. In our study intravenous procainamide 
succcs had only a 35% concordance with the results of oral 
therapy. In addition. fadure of intravenous procainamide to 
prevent arrhythmta inducihility had a 47% discordance with 
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oral therapy. The differences between our data and those of 
earlier studies may be partially explained by slightly !ower 
plasma concentrations. differences in patient groups. defini- 
lions of drug eficacy and stimulation protocols and uncer- 
tainly of the electropbysiologic potenzy of N-acetylprocaio- 
amide. The latter has been reported 110.13) as having lmle 
effect with respct to sustained arrhythmia induction and 
half the aotiarrhythmic potency of the parent drug. 
Other investig~~tors have repolred the inability if inkwe- 
nous procainamide to predict success with other oral agents. 
Oseran et al. (12) observed a 5% discordant response 
between imravenous procainamide and oral quinidine but a 
75% concordant response between oral procainamide and 
oral quinidine therapy in patients with sustained ventricular 
arrhythmias. In our study concordance between intmvenous 
and oral procainamide therapy in the two groups occurred in 
16 (42%) of the 38 patients. When patients were classified 
into discordant and concordant responder groups. there 
were no significant differences in patient characterisuci. 
ease of arrhythmia indocibility at baseline Study or eiection 
fraction. M&m ejection fraction for the concdrdan; group 
was 32 + 20% verses 32 2 14% for the o,scordanr prouo. 
lion as a guide to drug efficacy despite similar plasma drug 
levels between the intravenous and oral crow (8.1 i 2.7 vs. 
7.9 2 2.3 &ml). This observation u&c& a discrepancy 
betwcn plasma levels and myocardial effect heween oral 
and intravenous procainamidc. N-acetylprocainamide l vels 
were not routinely measured uring intravenous drug testing 
becaure they are characteristically tow during acme drug 
stud& and ~herrfore not comparable with levels achieved in 
the steady state with an oral dosing protocol. Plasma pro- 
cemarmde levels were measured at the end of the electro- 
phystolcgr study and may no1 have reflected increasing or 
decreasing shifts in plasma concentration after rhe loading 
and contmuou infusion of intravenous proainamide. la 
contrast. they aould have been virtually constant duringoml 
procainamide tertiog. Therefore. differences in levels be- 
tween mtrwenous and oral testing could have been greater 
than measured. accounting for some ofthe discordant results 
observed. 
With oral procainamide therapy there may be an eccumu- 
tation of active metabolites. as well Z,E an increased myocar- 
dxd drug concentration (14-16). Supporting this hypothesis 
is the variation in tachycardia cycle length observed in the 
patients in Group II who had concordant rerpmtses to 
intrwenous and oral therapy at similar plasma drug levels. 
These factors plus temporal differences in tissue concentra- 
Litttitaliarts and mechanisms. Acute drug testing with 
intravenous pmcainamide does not appear to predict out- 
come on oral therapy with programmed el. .irical >trmuIa- 
ular tachycardia on hbth intrwenou~ {IV) and oral 
therapy lpp~pt A) and inducible arrhythmia n mtrz- 
venous and noninducible wrhylhrma on omt therapy 
ipnnet B,. 
tions acbicved with i ~travenou loading, which a.rc depen- 
dent on local blood Row, may contribute lo the observed 
differences between intravenous and oral procainamidc 
(17~IYL 
Conclusions. Whatever the mechanisms involved. our 
data suggest brde advanmge 10 acute drug lesting in the 
eleclrophysiulogy laboratory with intravenous procainamide 
because of its inabdity to predict positive or negative out- 
come on subsequent oral therapy. 
